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Abstract
Background: Hepatic fibrosis is the underlying cause of cirrhosis and liver failure in nearly every form of chronic
liver disease, and hepatic stellate cells (HSCs) are the primary cell type responsible for fibrosis. Long noncoding
RNAs (lncRNAs) are increasingly recognized as regulators of development and disease; however, little is known
about their expression in human HSCs and their function in hepatic fibrosis.
Methods: We performed RNA sequencing and ab initio assembly of RNA transcripts to define the lncRNAs expressed
in human HSC myofibroblasts. We analyzed chromatin immunoprecipitation data and expression data to identify
lncRNAs that were regulated by transforming growth factor beta (TGF-β) signaling, associated with super-enhancers
and restricted in expression to HSCs compared with 43 human tissues and cell types. Co-expression network analyses
were performed to discover functional modules of lncRNAs, and principle component analysis and K-mean clustering
were used to compare lncRNA expression in HSCs with other myofibroblast cell types.
Results: We identified over 3600 lncRNAs that are expressed in human HSC myofibroblasts. Many are regulated by
TGF-β, a major fibrotic signal, and form networks with genes encoding key components of the extracellular matrix
(ECM), which is the substrate of the fibrotic scar. The lncRNAs directly regulated by TGF-β signaling are also enriched
at super-enhancers. More than 400 of the lncRNAs identified in HSCs are uniquely expressed in HSCs compared with
43 other human tissues and cell types and HSC myofibroblasts demonstrate different patterns of lncRNA expression
compared with myofibroblasts originating from other tissues. Co-expression analyses identified a subset of lncRNAs
that are tightly linked to collagen genes and numerous proteins that regulate the ECM during formation of the fibrotic
scar. Finally, we identified lncRNAs that are induced during progression of human liver disease.
Conclusions: lncRNAs are likely key contributors to the formation and progression of fibrosis in human liver disease.
Background
Liver fibrosis occurs as a result of chronic liver injury
and, if left unchecked, often proceeds to cirrhosis and
liver failure [1, 2]. Fibrosis develops as the result of accu-
mulation of extracellular matrix (ECM) proteins, includ-
ing collagen and glycoproteins [3–6], in a process that is
driven primarily by transforming growth factor beta
(TGF-β) signaling [7, 8]. Hepatic stellate cells (HSCs) are
the primary source of the ECM proteins that cause
fibrosis [9, 10]. In response to liver injury, quiescent
HSCs become activated and produce ECM proteins
[9, 11, 12]. When the source of liver injury is removed,
activated HSCs revert to an inactive phenotype, resulting
in reduced ECM protein expression [13, 14]. In chronic
liver disease, the continual activation of HSCs results in
differentiation into HSC myofibroblasts and constitutive
production of ECM proteins [2]. Collagen is the pri-
mary component of the fibrotic scar, and TGF-β is a
key signal that promotes collagen expression in HSC
myofibroblasts [15–17].
Differentiation of human HSCs into HSC myofibro-
blasts occurs in vivo in response to chronic liver injury
and this process can be modeled ex vivo by growth of
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HSCs on plastic [9, 11]. Quiescent HSCs are more buoy-
ant than other liver cells due to the presence of fat drop-
lets and can be isolated by density centrifugation [11].
Culture of quiescent HSCs on plastic results in morpho-
logical changes and induction of genes, including ACTA2
(actin, alpha2 smooth muscle), LOX (lysyl oxidase), and
LOXL2 (lysyl oxidase like 2), which are characteristic of
HSC myofibroblasts [18–21]. Despite an understanding of
the protein-coding genes that regulate fibrosis and devel-
opment of ex vivo tissue culture models to study this
process, there are still no effective treatments directed at
HSCs to inhibit fibrosis and prevent progression of liver
disease.
In recent decades, genome-wide studies have uncovered
evidence for extensive transcription outside the regions of
DNA that encode proteins [22]. Long noncoding RNA
(lncRNA) transcripts are greater than 200 nucleotides (nt)
in length and have the same structure as messenger RNAs
(mRNAs), including a 5′ cap and a polyadenylated 3′ tail,
but do not encode proteins [23]. Over 56,000 lncRNA loci
have now been described in human cells [24] and new
lncRNAs continue to be identified as new tissues and cell
types are analyzed. lncRNAs were originally described as
regulators of chromatin [25–27], but as increasing num-
bers of lncRNAs have been analyzed, it has become clear
that they play essential roles in many different cellular
processes [28–30]. They are also increasingly recognized
as key regulators in mammalian development and disease
[30–38], but very little is known about their role in liver
fibrosis.
In liver disease, lncRNAs have been studied primarily in
relation to cancer. HULC, MALAT-1, TUC338, TUC339,
lncRNA-HEIH, MVIH, HOTAIR, lnc-RoR, and HOTTIP
have all been associated with higher expression in hepato-
cellular carcinoma (HCC) compared with normal liver
tissue [39–48], while MEG3 is repressed in HCC [41]. Ex-
pression of MALAT-1, HOTAIR, and lncRNA-HEIH was
also found to be predictive of HCC recurrence [42, 43, 49]
and expression of HOTTIP correlates with metastatic
HCC burden [46]. HULC can be detected in peripheral
blood and TUC339 can be detected in extracellular
vesicles, suggesting that each might be able to serve
as biomarkers for HCC [39, 50]. Outside of cancer,
lnc-LALR1 is induced in mouse models of liver regen-
eration, where it promotes hepatocyte proliferation [51].
In addition, MEG3 is repressed in models of liver injury
and in response to TGF-β signaling in the HSC line LX2
[52] and GAS5 promotes p27 expression to inhibit HSC
proliferation and activation [53]. The lncRNAs associated
with liver disease were discovered by analyzing the expres-
sion of candidate lncRNAs [40, 43, 46] or by screening
panels of lncRNAs to identify known lncRNAs that are
preferentially expressed in HCC [39, 41, 42, 44, 45, 54].
These studies have not defined the full population of
lncRNAs that are expressed in HCC or in liver fibrosis
and instead have focused solely on characterizing
lncRNAs already described in other cell types.
Many lncRNAs follow cell type-specific patterns of
expression [55–57], yet no genome-wide analysis has
been performed to identify lncRNAs that are uniquely
expressed in HSCs. Thus, we performed RNA-sequencing
and ab initio assembly of RNA transcripts to define the
lncRNAs expressed in HSC myofibroblasts and those
regulated by TGF-β signaling. We analyzed proximity to
protein-coding genes, chromatin modifications, response
to TGF-signaling, cell type-specific patterns of expression,
and clustering by co-expression network analyses in order
to identify lncRNAs with the potential to regulate hepatic
fibrosis.
Methods
Cell culture
Fetal HSCs (Sciencell) were grown in Dulbecco’s modi-
fied Eagle medium (DMEM) with 10 % fetal calf serum
(FCS) and 1 % penicillin/streptomycin (P/S). Adult human
HSCs were isolated from fresh nonparenchymal liver cells
obtained from Triangle Research Laboratories. Nonpar-
enchymal cells were centrifuged at 50 × g for 5 minutes to
remove residual hepatocytes. The cells in the supernatant
were pelleted at 860 × g for 10 min before re-suspension
in Optiprep (Sigma) diluted to 15 % weight per volume
(w/v) with Hanks’ balance salt solution without calcium
or magnesium. Additional layers of 11.5 % and 8.5 % Opti-
prep solution were added to the centrifuge tube before
centrifugation at 1400 × g for 17 min with no brake. HSCs
were enriched at the interface between the 11.5 and 8.5 %
layers. These cells were removed and expanded in DMEM
with 10 % FCS and 1 % P/S. All work with primary human
cells was performed with approval of the Massachusetts
General Hospital Institutional Review Board (IRB). RNA-
sequencing analysis was performed on HSC myofibroblasts
after seven to eight passages. Induction of the quiescent-
like phenotype was performed by culturing HSCs in growth
factor reduced Matrigel (BD). Analysis was performed after
3 days in Matrigel for quantitative RT-PCR. HSCs treated
with TGF-β were grown in serum starvation conditions for
48 h in media containing DMEM with 0.2 % bovine serum
albumin (BSA) and 1 % P/S. Cells were treated with TGF-β
(2.5 ng/ml, R&D systems) for 16 h prior to harvest.
PCR analysis
RNA was isolated from HSCs using Trizol Reagent
(Life Technologies) followed by DNAse I digestion (Life
Technologies). RNA was reversed transcribed with
Superscript III (Life Technologies). Quantitative RT-PCR
analysis was performed with Taqman primer/probe sets
(Life Technologies) using the Bio-Rad CFX384 Real Time
System. ACTA2, LOX, LOXL2, and COL1A1 expression
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was normalized to GAPDH. The following Taqman
primer/probe sets were used: Hs_00426835, ACTA2;
Hs_00942480, LOX; Hs_00158757, LOXL2; Hs_00164004,
COL1A1; Hs_02758991, GAPDH.
Microscopy
Matrigel (200 μl, BD) was distributed across the surface
of each well of a 24-well plate and allowed to gel before
HSC myofibroblasts were added to the well. Activated
HSCs were plated on plastic. After 3 days, the medium
was aspirated, and Bodipy 493/503 (Life Technologies)
and Hoescht were diluted in media and added to the
wells. Bodipy was added at a concentration of 67 pg/μl
and Hoescht was added at a concentration of 5 pg/ul.
After 45 minutes, the cells were washed twice with
Dulbecco's phosphate-buffered saline (DPBS) and imaged
with a Nikon A1plus confocal microscope 10× lens. The
cells were observed using a pinhole setting of 255.4 μm.
Laser intensity, background level, contrast, and electronic
zoom size were collected at the same level for each experi-
ment. Image processing was performed using Adobe
Photoshop software.
Preparation of RNA-seq and ChIP-seq libraries
Total RNA was isolated using Trizol reagent followed by
clean up using either the MirVana® Isolation Kit (Life
Technologies) following instructions for total RNA iso-
lation or re-precipitation after phenol:chloroform and
choloroform extractions. RNA quality was assessed via
Agilent 2100 Bioanalyzer and samples with RNA integ-
rity numbers (RIN) greater than or equal to 9 were used
for library preparation. Isolated RNA was prepared for
sequencing according to TruSeq Stranded mRNA
Library Prep Kit (Illumina). Chromatin immunoprecipi-
tation (ChIP) was performed using antibodies to detect
enrichment of H3K4me3 (07-472, Millipore) and H3K27ac
(Ab4729, Abcam) as previously described [58] with the
following modifications: 1 × 107 cells were sheared for
5 min in 1 ml of cell lysis buffer (Covaris) using a Covaris
S220 set to a peak wattage of 140, duty factor 5 % and
200 cycles per burst; immunoprecipitations were per-
formed using 1 μg of antibody with 10 μl of magnetic
beads. ChIP-seq libraries were prepared using the TruSeq
ChIP Sample Prep Kit (Illumina). They were sequenced
using the Illumina HiSeq 2000 to obtain 100 × 100-nt
paired-end reads for fetal HSCs and used for ab initio
assembly (see below). Illumina HiSeq 4000 was used to
obtain 50-nt single-end reads for primary adult HSC myo-
fibroblasts. We used 50-nt single-end reads for ChIP-seq
analysis.
Ab initio assembly of transcripts from RNA-seq data
We mapped each replicate of directional paired-end RNA-
seq data to the human reference genome (hg19/GRCh37)
using TopHat v2.0.10 [59, 60] before assembling tran-
scripts using both Cufflinks [61] and Scripture [62]. The
TopHat settings were as follows:
tophat -p 8 –library-type fr-firststrand –mate-inner-
dist 50 –mate-std-dev 50 –microexon-search –GTF
genes.gtf -o < output-folder > <index of reference
genome > Reads_end1.fastq Reads_end2.fastq
The reference genes in GTF file format (genes.gtf) were
downloaded from the University of California, Santa Cruz
(UCSC) genome browser [63]. We then assembled tran-
scripts through the following settings of Cufflinks using
TopHat output bam file as input:
cufflinks -p 8 –max-bundle-frags 100000000 –library-
type fr-firststrand –frag-bias-correct –multi-read-
correct -o < output_folder > <tophat_output_bam_file>
Max-bundle-frags was set to 100,000,000 such that
highly expressed genes would be included in the output.
For analysis in Scripture, we used the following TopHat
settings:
tophat -p 4 –microexon-search –GTF genes.gtf -o
< output_folder > <index_of_reference_genome >
<Reads_one_end.fastq>
We used Scripture (beta2 version) to assemble tran-
scripts by following the protocol for transcript assembly
(http://www.broadinstitute.org/software/scripture/). All
transcripts assembled in Cufflinks and/or Scripture were
then merged into one list through Cuffmerge [61].
Identification of long noncoding RNAs
The assembled transcripts were then filtered through
the following steps to identify lncRNAs:
1. Removed transcripts that overlapped with annotated
protein-coding genes, pseudogenes, rRNAs, tRNAs,
small nucleolar RNAs (snoRNAs) and microRNAs
on the same strand.
2. Removed transcripts with protein coding potential.
The coding potential of each remaining transcript
was estimated by HMMER protein domain search
[64, 65] and CPAT [66] using an alignment-free
logistic regression model. The Pfam protein families
database (v27.0) was downloaded from EMBL-EBI
[67]. Both Pfam-A, containing high-quality and
manual curated families, and Pfam-B, containing
automatically generated comprehensive protein
families, were used in the HMMER domain search.
We removed the transcripts matching a protein
domain with p value <1e-4. CPAT uses a logistic
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regression model built with four sequence features:
open reading frame size, open reading frame coverage,
Fickett TESTCODE statistic, and hexamer usage bias
to estimate the coding ability of transcripts. We used
0.364 as the threshold for discriminating noncoding
and coding transcripts. This threshold (0.364) was
chosen because it gives the highest sensitivity and
specificity (0.966 for each) for human data [66]
according to the nonparametric two-graph receiver
operating characteristic (ROC) curves.
3. Removed remaining transcripts that overlapped on
the same strand with any transcripts removed in
steps 1 or 2.
4. Removed remaining transcripts that lacked
H3K4me3 occupancy within 1 kb of their 5′ end.
5. Removed remaining transcripts that were shorter
than 200 nt or had low read coverage as defined as
less than 0.01 reads per kilobase per million unique
mapped reads or less than ten reads per transcript.
ChIP-Seq analysis for HSCs
ChIP-seq datasets were aligned to the human reference
genome (hg19/G37) using Bowtie2 [68]. We performed
alignment in end-to-end alignment mode with the settings
“bowtie2 -k2 -N1 -L32 –end-to-end”. We next used the
MACS2 [69] callpeak function to compare the mapped
bam files of each ChIP to its matched whole cell extract
background control. H3K4me3 and H3K27ac peaks were
predicted using the following setting: -q 0.01 –nomodel
–shiftsize = 150. This setting was used because histone
marks have an underlying characteristic fixed resolution
for nucleosome size and our ChIP-seq only sequenced
50 nt at the 3′ end. SMAD3 ChIP-seq data from LX2 cells
were downloaded from the Gene Expression Omnibus
(GEO; accession GSM934613 and GSM934616) and
SMAD3 peaks were called by using the default settings in
MACS2. We defined genes as bound by SMAD3 if the site
of occupancy was within 10 kb upstream of the transcrip-
tion start site (TSS) or within the gene body.
Identification of super-enhancers
H3K27ac peaks that were called using MACS2 were
analyzed using ROSE [70, 71] to classify enhancers into
typical enhancers and super-enhancers based on H3K27ac
signals. The human reference genome (build hg19) and
H3K27ac peaks were used as input files. lncRNAs were
considered to be associated with super-enhancers or
typical enhancers if the enhancer was located within 10 kb
of the lncRNATSS.
Classification of lncRNAs
We classified lncRNA loci into four categories according
to their genomic locations. An lncRNA was classified as
divergent if the TSS of the lncRNA locus was within
2 kb of the TSS of a protein-coding gene on the opposite
strand. Any remaining lncRNAs that were antisense to a
protein-coding gene and overlapped the protein-coding
gene by one or more base pairs were classified as natural
antisense. Remaining lncRNAs located within a 1000-bp
window of a region of H3K27ac occupancy were classified
as enhancer-associated. Any remaining lncRNAs that had
a TSS greater than 2 kb from the TSS of the nearest
protein-coding gene were classified as intergenic.
Calculation of expression levels for protein-coding genes
and lncRNAs
The expression levels of all protein-coding genes and
lncRNA loci, represented in fragments per kilobase of
transcript per million fragments mapped (FPKM), were
calculated by Cuffdiff (v2.2.1) with the following pa-
rameters: “–max-bundle-frags 100000000 –library-type
fr-firststrand -b < hg19 reference genome > –multi-read-
correct –no-effective-length-correction –min-isoform-fraction
0 –min-alignment-count”. The max-bundle-frags setting
was increased from the default parameters so that
highly expressed genes would not be excluded.
Differential expression analyses
To increase the sensitivity in detecting changes in expres-
sion of protein-coding and lncRNA genes, two approaches
were used to quantify changes in expression: (a) TopHat
[59, 72] and Cuffdiff (v2.2.1) [61] and (b) HTSeq [73] and
DESeq2 [74]. We took the union of differential expressed
lncRNAs found either by Cuffdiff or DESeq2 (adjusted
p < 0.05). We used the FPKM values to quantify changes
in expression for all figures unless otherwise stated.
Comparison of lncRNAs and protein-coding gene
structure
To compare the number of exons, transcript lengths,
and gene lengths between lncRNAs in HSCs and protein-
coding genes, the longest isoform for each locus was
selected to represent an lncRNA or protein-coding gene.
All protein-coding genes expressed in HSCs were used for
these comparisons.
Raw RNA-seq data of other human tissues and cell types
We obtained the raw RNA-seq data for 37 human tis-
sues (see Additional file 1: Table S1 for tissue name and
GTEx ID) and dermal fibroblasts from dbGaP [75].
RNA-seq data from the six tier 1 and tier 2 Encyclopedia
of DNA Elements (ENCODE) cell lines were down-
loaded from GEO. GM12878, K562, HeLa-S3, HepG2,
and human umbilical vein endothelial cell (HUVEC)
data were obtained from GSE26284 and H1 (WA01)
human embryonic stem cell data from GSE41009. RNA-
seq data of pancreatic stellate cells and immortalized
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human induced fibroblast (hiF-T) cells were downloaded
from GSE43770 and GSE62777, respectively.
Analysis of lncRNA expression across tissues and cell
types
Three samples were selected from each of 37 distinct
human tissues from the Genotype-Tissue Expression
(GTEx) project [75] and downloaded from dbGaP. The
HSC myofibroblasts analyzed in this study were male, so
the two male and one female samples with the highest
number of reads were selected for each tissue (Additional
file 1: Table S1). Where tissues were male- or female-
specific, all three samples were selected from the same
sex. The FPKM values for protein-coding and lncRNA
genes were used to quantify changes in expression. The
Wilcoxon–Mann–Whitney test was used to identify the
lncRNAs overexpressed in HSC myofibroblasts and HSC
myofibroblasts treated with TGF-β compared with 37
human tissues and six ENCODE cell lines. The dendro-
gram for clustering the human samples was calculated
by the default setting of the R function heatplot (in the
gplots and made4 libraries of R).
RNA-seq data from 35 liver samples from GTEx [75]
were downloaded from dbGaP. The pathology reads
were obtained from GTEx. Of the 35 liver samples, eight
showed normal histology, two showed bridging fibrosis,
and two showed cirrhosis (Additional file 2: Table S2).
These 12 samples were selected for further analysis. The
Z-score was calculated by subtracting the mean expres-
sion of an lncRNA for each row from the individual ex-
pression level of the lncRNA in a sample and dividing by
the standard deviation.
Generation of BigWig files
Fetal HSC RNA-seq data and the RNA-seq data of six
ENCODE cell types are directional, paired-end data and
both paired-end reads were mapped independently to
the reference genome (hg19) in order to retain strand-
specific information for HSC and ENCODE RNA-seq
data. In this way the second-strand sequence was mapped
to the genome and the reverse complement of the first-
strand sequence was mapped to the genome. We then
converted the mapped reads with strand information into
BigWig files.
The RNA-seq data from GTEx is undirectional paired-
end data, so we mapped both end reads into the human
reference genome without strand information. BigWig
files for ENCODE and GTEx were generated using
TopHat to align to the genome with the setting “–N 0”,
which was necessary to exclude a peak in this region
that mapped to multiple genomic locations.
We used the “bdgcmp” function of MACS2 to subtract
the whole-cell extract background sequencing reads
from the ChIP-seq reads using the log-likelihood ratio
(logLR) method, which calculates the log10 likelihood
ratio between the ChIP and whole-cell extract. All ChIP
and whole-cell extract background sequencing reads were
normalized by their sequencing depths. We then con-
verted the mapped reads into BigWig files.
Co-expression analysis and network construction
We constructed the co-expression networks for lncRNAs
and all protein-coding genes from RefSeq (version of 10
Feb 2014) using the mcxarray program in the Markov
Clustering (MCL)-edge network analysis tool [76] (http://
micans.org/mcl/) with Spearman correlation. Gene ex-
pression was calculated using Cuffdiff (see the previous
section in the “Methods” for details). In this study, we
choose 0.7 as the Spearman correlation cutoff in order to
balance the number of singletons and the median node
degree as recommended by the MCL protocol. To make
the co-expression analysis consistent through the entire
project, we used the same correlation and threshold to
examine if the divergently transcribed coding genes and
lncRNAs are co-expressed.
We adopted the MCL algorithm to identify clusters
from the constructed large networks. The MCL algo-
rithm is coded in the mcl program [76], which is a fast
and scalable unsupervised cluster algorithm for networks
based on simulation of stochastic flow in networks. The
default granularity “–I 1.4” was set for MCL clustering.
Cytoscape v3.1.1 [77] was used to visualize the connected
networks and clusters.
For the nucleotide-binding module, all the protein-
coding genes annotated in the Gene Ontology (GO)
nucleotide binding category in cluster I and their directly
co-expressed lncRNAs (linking by one-edge) in cluster I
were selected to be displayed. For the extracellular
matrix module, all the protein-coding genes annotated
in the GO extracellular matrix category in cluster II and
their directly co-expressed lncRNAs (linking by one-
edge) in cluster II were selected to be displayed.
GO enrichment analyses
GO enrichment analysis was performed using the protein-
coding genes identified in each co-expression cluster
(http://david.abcc.ncifcrf.gov/) [78, 79]. All protein-coding
genes used in the network construction were used as the
background in the GO enrichment analyses.
Statistical analysis
The p values in this study were calculated by Wilcoxon–
Mann–Whitney test, unless otherwise mentioned.
Principal component analysis
We used pricipal component analysis (PCA) to examine
the similarity in expression patterns of lncRNAs among
the indicated cell types and to examine the similarity in
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expression patterns of lncRNAs plus protein coding
genes between the same cell types. Each replicate for
each sample is represented with a vector of the expres-
sion levels of the indicated genes. All principal compo-
nents (PCs) were identified for each replicate through
PCA on its expression vector. We then used the k-mean
method to cluster the replicates of all samples according
to the first three major components. Graphs display the
first and second major components (PC1 and PC2) or
the first and third major components (PC1 and PC3) in
two dimensions.
Identification of enhancer-RNAs
To identify the enhancer-RNAs (eRNAs), we down-
loaded the H3K4me3 and H3K4me1 ChIP-seq data for
hiF-T cells (GSE62777). We excluded lncRNAs expressed
in HSC myofibroblasts that were classified as divergent
or natural antisense from eRNA analysis because their
histone marks cannot be distinguished from marks of
neighboring genes [80]. For the remaining lncRNAs, we
selected those that are also expressed in hiF-T cells
according to their calls by Cuffdiff. Next, we mapped
the raw H3K4me3 and H3K4me1 reads to the TSS
regions of each lncRNA (defined as within ±500 bp of
the TSS) and then calculated the H3K4me1/H3K4me3
ratio for each lncRNA. A ratio of >1.2 was used to
define eRNAs, as previously described [80].
Data access
RNA-seq and ChIP-seq data produced for this study are
available in the GEO (accession GSE68108).
Results
De novo identification of lncRNAs in human HSCs
We first established that primary human fetal HSC myofi-
broblasts share characteristics described for HSCs. These
cells were chosen for initial analysis as they could be
expanded more easily for genome-wide sequencing. Cul-
ture in Matrigel repressed ACTA2, LOX, and LOXL2
expression and induced accumulation of lipid droplets
characteristic of the reversion to an inactive HSC pheno-
type in Matrigel (Fig. 1a, b) [81, 82]. These HSCs also
showed induced collagen expression in response to TGF-β
signaling (Fig. 1c) [15]. We then performed massively par-
allel sequencing of polyadenylated RNAs (RNA-seq) to
identify lncRNAs that are expressed in human HSC myo-
fibroblasts. Directional libraries were prepared for paired-
end sequencing so that overlapping sense and antisense
transcripts could be distinguished from one another dur-
ing analysis. We then established a computational pipeline
for ab initio construction of lncRNA transcripts (Fig. 1d)
[58, 62, 83]. RNA-seq reads were first aligned to the gen-
ome with TopHat [59, 60]. Cufflinks [61] and Scripture
[62] were each used to assemble the aligned reads into
transcripts, which were then merged by Cuffmerge
[60, 61]. All assembled transcripts that overlapped on
the same strand with protein-coding genes in RefSeq
[84] or the UCSC database [85] were removed, as
well as those overlapping with rRNAs, tRNAs, micro-
RNAs and snoRNAs annotated in RefSeq. The remaining
transcripts were analyzed by a HMMER profile search of
protein domains [64, 65] and CPAT software with a logis-
tic regression model [66] to assess their protein-coding
potential (Additional file 3: Figure S1). Transcripts that
had low protein-coding potential as predicted by both
HMMER and CPAT were considered to be noncoding
RNAs. We next performed ChIP-seq using an antibody
against the chromatin mark H3K4me3 to identify sites of
transcription initiation [86]. All RNA transcripts whose 5′
ends were greater than 1 kb from an H3K4me3 site were
removed because the absence of a proximal transcription
initiation mark suggested that the assembled RNA tran-
scripts might be incomplete. All transcripts less than
200 nt in length and below expression thresholds were
removed (see “Methods” for additional details). We identi-
fied and assembled 7189 lncRNA transcripts into 2808
lncRNA loci (Additional file 4: Table S3).
Two lncRNAs identified with this pipeline are shown
in Fig. 1e. lncRNA-054349 (top) is an example of a three-
exon lncRNA that was not previously annotated and
EPHA5-AS1 is an example of a lncRNA for which a single
isoform was previously annotated. For both lncRNAs,
H3K4me3 occupancy is shown in black (top) and the
RNA-seq reads supporting the lncRNAs are shown in red
(sense). The genomic structure of each lncRNA is indi-
cated below the tracks in red, with arrows indicating the
direction of transcription. EPHA5-AS1 is divergently tran-
scribed from EPHA5 and the RNA-seq reads supporting
EPHA5 transcripts are indicated in blue (antisense).
Genomic characterization of lncRNAs
We next assessed the distribution of lncRNAs across the
genome. Over 65 % of HSC lncRNAs were divergently
transcribed from the promoter regions of protein-coding
genes. Four percent of the total identified lncRNAs were
antisense to coding genes (natural antisense), 10 % were
located at enhancers as defined by the presence of
H3K27ac [87], and 15 % originated from intergenic
regions away from coding genes (Fig. 2a). Plotting the
location of the transcriptional start site (TSS) of each
lncRNA relative to the TSS for the closest protein-
coding gene showed that the vast majority of lncRNAs
are transcribed antisense to protein-coding genes and
originate near the promoter of these genes (Fig. 2b), with
the TSS of the lncRNAs located a mean distance of 135 nt
upstream of the TSS of the paired protein-coding genes.
We also found that lncRNAs in HSCs tend to be
expressed at lower levels than protein-coding genes.
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Analysis of the expression level of lncRNAs and their di-
vergently transcribed mRNAs showed that lncRNAs are
expressed at approximately tenfold lower levels than
protein-coding genes (Fig. 2c; p < 2.2e-16). These findings
are consistent with the description of lncRNAs in other
cell types [55, 56, 58, 88].
Most of the identified lncRNA transcripts (>55 %)
are single exon transcripts whereas only 4 % of
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protein-coding genes expressed in HSC myofibroblasts
are encoded by single exons (Fig. 2d). HSC lncRNAs also
tend to have shorter genes and shorter transcripts than
protein-coding genes (Additional file 3: Figure S2) [88].
Super-enhancers are large domains of active enhancers
associated with genes that control cell identity [70, 71].
To identify lncRNAs that may regulate key facets of
HSC identity and function, we asked if lncRNAs are
associated with super-enhancers in HSCs. We performed
ChIP-seq to identify regions of chromatin containing
the histone modification H3K27ac, which is enriched
at active enhancers [87]. We identified 7339 typical
enhancers and 321 super-enhancers (Additional file 5:
Table S4) according to their H3K27ac signal strengths
(Fig. 2e). These super-enhancers are an order of magni-
tude larger than typical enhancers in genomic coverage
(Fig. 2f) and have larger peaks of H3K27ac enrichment
than typical enhancers (Fig. 2g). Super-enhancers are also
associated with lncRNAs identified in HSCs; for example,
lncRNA-002221 is located within a super-enhancer that
spans greater than 20 kb (Fig. 2h). Eighty lncRNAs discov-
ered in HSC myofibroblasts were found to be associated
with super-enhancers. H3K27ac signal at these super-
enhancers associated with lncRNAs also shows increased
genomic coverage (Fig. 2i) and larger peaks than typical
enhancers (Fig. 2j).
TGF-β signaling directly regulates lncRNA expression in
HSC myofibroblasts
TGF-β is a key regulator of fibrosis in liver disease [15–17]
and we next asked if TGF-β signaling regulates expression
of lncRNAs in HSC myofibroblasts. HSC myofibroblasts
were serum starved for 48 h to remove exogenous TGF-β
from the media, followed by treatment with TGF-β for
16 h (Fig. 3a). RNA was harvested from HSC myofibro-
blasts that were treated with TGF-β after serum starvation
and from HSC myofibroblasts that remained in serum
starvation conditions. We performed RNA-seq analysis to
confirm that TGF-β treated HSCs respond to TGF-β
signaling (Additional file 3: Figure S3a) and then used our
computational pipeline (Fig. 1d) to assemble the lncRNAs
expressed during serum starvation (low TGF-β) and after
TGF-β treatment. Wer assembled 2078 lncRNA loci in
serum-starved HSC myofibroblasts and 1759 lncRNA loci
after TGF-β treatment (Additional file 3: Figure S3b).
The lncRNA transcripts defined in HSC myofibroblasts,
serum-starved HSC myofibroblasts, and TGF-β-treated
HSC myofibroblasts were combined using Cuffcompare
[60, 61] to define a total of 16,299 lncRNA transcripts
expressed in at least one condition. These transcripts were
classified into 3692 lncRNA loci and represent all the
lncRNA loci detected in human HSCs (Additional file 6:
Table S5 and Additional file 7: Table S6). Many of these
(See figure on previous page.)
Fig. 2 Genomic and expression features of HSC lncRNAs. a Classification of lncRNA loci identified in HSC myofibroblasts. Divergent lncRNAs
are defined as having a transcription start site (TSS) within 2 kb of the TSS of a protein-coding gene and being transcribed from the strand
antisense to the protein-coding gene. Natural antisense lncRNAs overlap the coding gene by at least one base pair. Enhancer-associated lncRNAs
are located within 1 kb of an enhancer as defined by H3K27ac. Intergenic lncRNAs have a TSS greater than 2 kb from the TSS of the nearest
protein-coding gene and are not contained in any of the other categories. lncRNAs are indicated in red and protein-coding genes are indicated
in blue. Arrows show the start and direction of transcription. H3K72ac (K27ac) peaks mark enhancers. The abundance of each class of lncRNA is
displayed on the right. b Distribution of the TSS of lncRNAs relative to the TSS of their nearest protein-coding gene. All protein-coding genes
were normalized to equal length on the x-axis (black rectangle), and 10 kb of genomic sequence upstream of the TSS of each protein-coding
gene is shown. The location of the TSS of each lncRNA was plotted relative to the TSS of the nearest protein-coding gene. lncRNAs that are
antisense to protein-coding genes are indicated in red and lncRNAs that are sense to protein-coding genes are indicated in blue. The red peak
near the protein-coding TSS indicates that the majority of lncRNAs are located within 2 kb of protein-coding genes and transcribed antisense to
protein-coding genes. c lncRNAs (red) are expressed about tenfold lower than their divergent protein-coding genes (blue). The expression levels
(log2 transformed reads per fragment per million mapped reads (FPKM)) are indicated on the y-axis. The horizontal black line indicates the mean
and open circles indicate outliers. d lncRNAs contain fewer exons than protein-coding genes. The distribution of exons in lncRNA (red) and mRNA
(blue) transcripts. e Identification of super-enhancers in HSC myofibroblasts. Enhancers were defined by H3K27ac occupancy and ranked from
left to right (x-axis) by the total reads of H3K27ac mapped to each enhancer (H3K27ac signal, y-axis). We identified 321 super-enhancers from a
total of 7660 enhancers [70]. f Super-enhancers show broad domains of occupancy compared with typical enhancers. Metagenes represent the
mean H3K27ac density (in reads per million unique mapped reads per base pair) across super-enhancers (left) and typical enhancers (right). The
metagenes are centered on the enhancer region for each plot and display 3 kb of sequence flanking each enhancer. The median size of a
super-enhancer is 18,807 bp and the median size of a typical enhancer is 678 bp. The plots are scaled (x-axis) to reflect the median size of the
two classes of enhancers. The increase of signal at the boundary is characteristic of super-enhancers [71] because the boundary represents the
H3K27ac peaks at the edges of each super-enhancer. Thus, the peaks at the boundary tend to be aligned with each other while peaks away from
the boundaries are distributed more equally. g H3K27ac peaks are enriched at super-enhancers. Metagenes represent the mean H3K27ac density
across the major peak of super-enhancers (SE) and typical enhancers (TE). h Example of an lncRNA associated with a super-enhancer. H3K27ac
occupancy (normalized logLR value, y-axis) is shown surrounding lncRNA-002221 (red). The domain of the super-enhancer is indicated by a red
rectangle. i Super-enhancers were found to be associated with 80 lncRNAs. The median size of super-enhancers associated with lncRNAs was
18,699 bp and the median size of typical enhancers associated with lncRNAs was 1032 bp. We located 968 lncRNAs within 10 kb of a typical
enhancer. The enhancers were plotted as described in f. j H3K27ac peaks are enriched at super-enhancers associated with lncRNAs. Metagenes
represent H3K27ac density across the major peak of super-enhancers and typical enhancers associated with lncRNAs
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lncRNAs are novel, including 40 % that do not overlap
with a single nucleotide of human lncRNAs annotated in
existing databases (Additional file 3: Figure S3c).
We identified 139 lncRNA loci that were induced and
242 lncRNA loci that were repressed with activation of
TGF-β signaling (Fig. 3b; p < 0.05). The transcription fac-
tors SMAD2 and SMAD3 are activated by TGF-β
signaling to mediate the transcriptional effects of the
canonical TGF-β signaling pathway [89] and SMAD3
appears to play the dominant role in HSC myofibroblast
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Fig. 3 Regulation of HSC lncRNAs. a Conditions for HSC lncRNA analysis. HSC myofibroblasts were cultured for 48 h in 0.2 % bovine serum albumin to
remove exogenous TGF-β from the media (low TGF-β) and then treated with TGF-β for 16 h to define lncRNAs regulated by TGF-β signaling. b lncRNA
expression in response to TGF-β signaling. The heatmap shows normalized expression of lncRNAs that were induced (red) or repressed (green)
in response to TGF-β signaling. The Z-score is shown on the right and was calculated from expression of lncRNAs in two replicates of low
TGF-β conditions (not shown) and two replicates of TGF-β treatment (shown). Each row represents one lncRNA locus and lncRNA loci are
ranked by p value such that the smallest p value of induced lncRNAs is at the top and the smallest p value of repressed lncRNAs is at the
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shown at the top. RNA-seq reads (red) are displayed for HSCs in low TGF-β and after 16 h of TGF-β signaling. The structure and direction of
lncRNA-000509 is shown below. d lncRNAs that are regulated by TGF-β signaling tend to be occupied by SMAD3. The fraction of lncRNA genes
that are induced (left) and repressed (right) by TGF-β and are occupied by SMAD3. Genes that are regulated in response to TGF-β signaling
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(Indirect target) are associated with typical enhancers (Typical E)
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activation [12]. To determine the direct targets of TGF-β
signaling, we identified the lncRNAs that were regulated
by TGF-β and occupied by SMAD3. For example,
lncRNA-000509 is occupied by SMAD3 and shows a ten-
fold induction between serum starvation (low TGF-β) and
induction of TGF-β signaling (Fig. 3c). Sixty-six percent of
lncRNAs induced by TGF-β (p < 3e-12) and 43 % of
lncRNAs repressed by TGF-β (p < 0.015) were found to be
occupied by SMAD3 in the human HSC line LX2, follow-
ing TGF-β treatment [90] (Fig. 3d). This analysis identified
91 lncRNAs that are directly induced by TGF-β signaling
and 104 lncRNAs that are directly repressed by TGF-β
signaling, with a mean induction and repression of two-
fold (Additional file 8: Table S7).
TGF-β signaling targets cell type-specific enhancers
bound by master transcription factors [91] and super-
enhancers regulate genes that define cell identity [70, 71].
We also found that lncRNAs directly targeted by TGF-β
signaling (regulated by TGF-β and occupied by SMAD3)
are more likely to be associated with super-enhancers in
HSCs than lncRNAs indirectly targeted by TGF-β signal-
ing (Fig. 3e; p < 6.3e-6), suggesting that these lncRNAs
may also play a key role in cell identity. Coding genes
directly targeted by TGF-β signaling are also more likely
to be associated with super-enhancers than indirectly tar-
geted genes (p < 5.9e-14). However, lncRNAs that are dir-
ectly targeted by TGF-β signaling are more likely to be
regulated by super-enhancers than coding genes directly
targeted by TGF-β (p < 1.6e-13).
lncRNAs enriched in HSC myofibroblasts
lncRNAs appear to be under weaker evolutionary con-
straints than protein-coding genes, resulting in more cell
type-specific patterns of expression compared with coding
genes [55–57]. While approximately 40 % of the 3692
lncRNA loci identified in HSCs were not described in
other lncRNA databases (Additional file 3: Figure S3c), it
is unclear if this result means that these lncRNAs are
unique to HSCs or that many of these lncRNAs are
expressed in other cell types but have not been described.
To define the lncRNAs specific to HSCs, we examined the
expression patterns of lncRNAs identified in HSC myofi-
broblasts and HSC myofibroblasts treated with TGF-β
compared with 37 other human tissues [75] and the six
tier 1 and tier 2 cell lines from the ENCODE project [92].
Analyses revealed that more than 400 lncRNAs are
significantly enriched in HSCs compared with the 43
other tissues and cell types analyzed (Fig. 4; p < 0.05;
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Fig. 4 Expression of HSC-specific lncRNAs. The normalized expression levels are shown for 435 lncRNAs (y-axis) that are enriched in HSCs compared
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Additional file 9: Table S8). This enrichment is observed
relative to primary tissue, including liver, and six cell lines,
including the hepatocellular carcinoma cell line HepG2.
For example, lncRNA-001762 is expressed at greater than
sixfold higher levels in HSC myofibroblasts treated with
TGF-β compared with the highest level of expression in
43 other tissues and cell lines (Fig. 5a). The FPKM for
lncRNA-001762 in HSC myofibroblasts is 2.9 and in-
creases to 5.4 with TGF-β treatment, whereas the mean in
all other samples is 0.13 with maximum expression of
0.85 in human umbilical vein endothelial cells (HUVECs).
The restriction in expression to HSCs is further illustrated
by visualizing the RNA-seq reads mapped to lncRNA-
001762 in the HUVEC cell line and testis (Fig. 5b).
These examples were chosen because they are the cell
line and primary tissue with the next highest expres-
sion of lncRNA-001762 compared with HSC myofibro-
blasts. Whole liver tissue and the HepG2 cells express
even lower levels of lncRNA-001762, which suggests that
this lncRNA is likely restricted in expression to HSCs in
the liver and is not induced in hepatocellular carcinoma.
lncRNAs expressed in HSCs are enriched in ECM networks
Co-expression network analyses have been used widely
to predict the functions of unknown coding and noncod-
ing genes [93–100] based on the expectation that genes
with similar expression patterns across multiple tissues,
cell types, or conditions share similar functions or are in-
volved in related biological processes [101, 102]. There-
fore, we conducted co-expression network analyses across
the 37 primary human tissues, six ENCODE cell lines, and
the HSCs described in this study using expression profiles
for all annotated genes expressed in at least one tissue or
cell type and the lncRNAs identified in this study.
We identified 169 subnetworks containing at least two
nodes where each node represents a protein-coding gene
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or an lncRNA and the edge between two nodes indicates
that the two genes are co-expressed with a Spearman-
correlation coefficient >0.7 (p < 4e-7; Fig. 6a). Most of
the identified subnetworks were small and only five
contained more than five nodes. To identify the subnet-
works that would provide the most information about
lncRNAs acting in HSCs, each subnetwork was scanned
for HSC identity lncRNAs that were defined as lncRNAs
proximal to super-enhancers, occupied by SMAD3, and
restricted in expression to HSCs (Additional file 10:
Table S9). Thirty-three lncRNAs met these criteria and 21
were contained in subnetwork A. HSC identity lncRNAs
were not found in any of the other subnetworks. Subnet-
work A contains 18,002 nodes and was decomposed to
identify smaller clusters that may provide further insight
into the function of lncRNA genes. Nine clusters were
identified based on their connection structure and correl-
ation value (see “Methods” for details) and three clusters
contained more than one HSC identity lncRNA. Cluster I
contained 3950 nodes, including two identity lncRNAs
and 332 lncRNAs expressed in HSCs. Cluster II contained
1865 nodes, including nine identity lncRNAs and 314
lncRNAs expressed in HSCs. Cluster IV contained 48
nodes, including two identity lncRNAs and seven lncRNAs
in HSCs.
We then performed gene ontogeny (GO) enrichment
analysis on clusters I, II, and IV to identify cellular pro-
cesses or functions that were key components of each
cluster. Cluster I was heavily enriched in nucleotide
binding (Fig. 6b), cluster II in ECM (Fig. 6c) and cluster
IV in DNA binding factors (Fig. 6d). We visualized clus-
ter I to show the size of the network and the relative
composition of mRNA and lncRNA genes by mapping
all protein-coding genes from cluster I that were con-
tained in the nucleotide-binding category and all the
lncRNAs in cluster I within one edge of these protein-
coding genes. This nucleotide-binding functional module
is composed of 521 genes encoding mRNA (blue) and 262
genes encoding lncRNAs (red) (Fig. 6e). We visualized the
ECM functional module in cluster II by mapping all
protein-coding genes from cluster II that were contained
in the ECM category and all the lncRNAs in cluster II
within one edge of these protein-coding genes. This ECM
module is more enriched for lncRNAs, being composed of
110 genes encoding mRNAs and 211 genes encoding
lncRNAs (Fig. 6f). We visualized cluster IV by showing all
protein-coding genes and lncRNA genes in that cluster.
Cluster IV is enriched in HOX transcription factor genes
(dark green) and known lncRNA genes associated with
HOX loci (light green) (Fig. 6g). Lists of individual genes
encoding mRNAs and lncRNAs and the co-expression
pairs related to each GO category (nucleotide binding in
cluster I, ECM in cluster II and Cluster IV) are included
in Additional file 11: Table S10.
The most significant finding from this analysis is that a
module of genes encoding mRNAs and lncRNAs is highly
associated with the ECM, whose production by HSC myo-
fibroblasts is the primary cause of liver fibrosis and pro-
gression to liver failure in chronic liver disease [9, 10]. To
exclude the possibility that the presence of protein-coding
genes and lncRNAs highly enriched in HSCs skewed the
co-expression network analysis, we repeated the analysis
without the HSC data. This analysis also yielded the ECM
module within cluster II, demonstrating that this is a
robust functional module even in the absence of HSC
expression data (Additional file 3: Figure S6).
Twelve HSC identity lncRNAs were present within
one edge of protein-coding genes in cluster II that were
associated with ECM (Fig. 6h). This sub-cluster is highly
enriched in genes related to liver fibrosis, including 11
collagen genes and genes encoding TGFB1, matrix me-
talloproteinases, tissue inhibitors of metalloproteinases,
and lysyl oxidase like proteins. These findings suggest
that the 12 identity lncRNAs in this sub-cluster likely
contribute to ECM production and liver fibrosis.
We then asked if coordinated expression of coding
and noncoding genes within super-enhancers could ex-
plain the structure of the co-expression networks.
Cluster I and cluster II contained 30 paired genes encod-
ing lncRNAs and mRNAs that were co-expressed and
located in the same super-enhancers, but these examples
were almost entirely associated with divergently tran-
scribed genes that were located in a super-enhancer. In
contrast, cluster IV did contain two super-enhancers
where multiple mRNAs and lncRNAs were co-expressed
(Fig. 6i). While cluster IV does contain examples of co-
expressed genes within super-enhancers, association within
super-enhancers appears to account for only a small frac-
tion of co-expressed genes.
The majority of lncRNAs expressed in HSC myofibro-
blasts are divergently transcribed from genes that encode
proteins (Fig. 2a). We found that over 90 % of divergent
lncRNAs expressed in HSCs were paired with protein-
coding genes that are also expressed in HSCs (Additional
file 12: Table S11). We analyzed expression of each
lncRNA and the paired protein-coding gene across 37 pri-
mary tissues [75] and the six tier 1 and tier 2 cell lines
from the ENCODE project [92] and found that only 14 %
of these pairs are co-expressed across tissues (Spearman
correlation >0.7, p < 4e-7; Additional file 13: Table S12).
Thus, in many cell types where a protein-coding gene is
expressed, the divergent lncRNA identified in HSCs is
silent.
lncRNAs expressed in fetal HSCs exhibit expression
patterns similar to those in adult HSCs
The lncRNAs analyzed in this study were defined in
human fetal HSCs myofibroblasts and we next asked if
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these findings also apply to adult HSC myofibroblasts.
We performed RNA-sequencing to quantify expression
of lncRNAs in primary human HSCs that were transdif-
ferentiated into HSC myofibroblasts by ex vivo culture.
Over 96 % (3566 out of 3691) of lncRNAs detected in
fetal HSC myofibroblasts were also detected in adult
HSC myofibroblasts (Additional file 14: Table S13). The
435 lncRNAs that were uniquely enriched in fetal HSC
myofibroblasts (Fig. 4) were also highly enriched in adult
HSC myofibroblasts (Fig. 7a). We then asked if these
lncRNAs were specific to HSC myofibroblasts or were
also expressed in myofibroblasts originating in other
tissues. We found that pancreatic stellate cells [103] and
dermal fibroblasts [75] also expressed many lncRNAs in
common with fetal HSC myofibroblasts (Additional
file 3: Figure S7a, Additional file 14: Table S13). How-
ever, lncRNA expression in fetal HSC myofibroblasts
was more closely associated with lncRNA expression
in adult HSC myofibroblasts compared with pancre-
atic stellate cell myofibroblasts (p < 1.23 e-7) or der-
mal fibroblasts (p < 8.8e-6) and is also shown by PCA
(Fig. 7b). This association was also present when tak-
ing into account expression of both lncRNAs and
protein-coding genes (Additional file 3: Figure S7b).
In addition, adult HSC myofibroblasts stimulated with
TGF-β signaling showed similar patterns of gene in-
duction and repression compared with fetal HSC
myofibroblasts treated with TGF-β (Additional file 3:
Figure S7c, Additional file 15: Table S14).
Cluster II (Fig. 6f ) contains the lncRNAs that form a
network with ECM proteins. Adjusting this network to
contain lncRNAs expressed in adult HSC myofibroblasts
led to removal of only four lncRNAs (Additional file 3:
Figure S7d). We then analyzed expression of the lncRNAs
in the ECM module across normal human liver tissue,
bridging fibrosis, and cirrhosis. This analysis identified 16
lncRNAs that were expressed in both fetal and adult HSC
myofibroblasts and were significantly enriched in human
liver fibrosis and cirrhosis compared with normal livers
(Fig. 7c), suggesting that induction of these lncRNAs is
associated with progression of human liver fibrosis. It also
indicates that the ECM module is enriched in lncRNAs
induced in bridging fibrosis and cirrhosis (7.6 %) com-
pared with the total lncRNA pool in HSCs (1.4 %).
A small fraction of the noncoding RNAs identified in HSCs
can be classified as unidirectional eRNAs
lncRNAs were identified in this study by the presence
of polyadenylation and size greater than 200 nt. eRNAs
are noncoding RNAs (ncRNAs) transcribed from en-
hancers and tend not to be polyadenylated or spliced
[104]. They can be transcribed unidirectionally or bidirec-
tionally and unidirectional eRNAs can be polyadenylated
[105]. The functional differences between polyadenylated
unidirectional eRNAs and lncRNAs transcribed from
enhancers are not clearly understood [106], but the abun-
dance of the chromatin mark H3K4me1 compared with
H3K4me3 has been used to classify these ncRNA tran-
scripts [22, 80]. To determine the fraction of lncRNAs
identified in this study that overlap with polyadenylated
unidirectional eRNAs, we analyzed ChIP-seq data of
H3K4me1 and H3K4me3 in immortalized human in-
duced fibroblasts (hiF-Ts) [107]. Of the 1042 lncRNAs
identified in HSCs and classified as enhancer-associated
or intergenic (Fig. 2a), 851 were also expressed in hiF-Ts.
Using the H3K4me1:H3K4me3 ratio >1.2 as the threshold,
we found that 181 of 851 ncRNAs (21 %) meet the defin-
ition of eRNAs (Fig. 7d; Additional file 16: Table S15) [80]
and 90 of these loci encode only single exon ncRNAs. It is
not clear if these unidirectional eRNAs may have different
activities to lncRNAs, but eRNAs accounted for only
5.6 % of lncRNAs in the ECM functional module (Fig. 6f)
and removal of these eRNAs led to loss of two additional
protein-coding genes from the ECM module (Additional
file 3: Figure S7d and Additional file 11: Table S10).
Discussion
HSCs are the primary cell type responsible for liver
fibrosis and liver failure in chronic liver disease. While
many protein-coding genes that regulate HSC function
have been described, the diversity of lncRNA expression
in HSCs and the biological pathways they affect are un-
known. This study was performed to define the lncRNAs
expressed in human HSCs and to predict those that are
likely to regulate the fibrotic process. Identification of
lncRNAs uniquely enriched in HSCs will provide poten-
tial targets to inhibit the progression of fibrosis without
affecting other cell types in the liver.
We also find that many lncRNAs are expressed diver-
gently from protein-coding genes, as previously described
[55, 58]. While our analysis does not address co-expression
of the paired protein-coding and lncRNA genes at the
single cell level [108], it does suggest that the lncRNAs
and their divergent protein-coding genes are usually
both expressed is HSCs. In contrast, a minority of these
paired lncRNA and protein-coding genes are co-expressed
across different cell types. Thus, while a protein-coding
gene may be expressed in many different cell types, the
expression of its paired, divergent lncRNA appears to be
more restricted, suggesting that there are cell type-specific
levels of lncRNA gene regulation independent of the tran-
scriptional control of the divergent protein-coding gene.
Our analysis also identified 195 lncRNAs that are dir-
ectly affected by TGF-β signaling as indicated by SMAD3
occupancy [90] and change in expression in response to
TGF-β signaling. In addition, lncRNAs directly regulated
by TGF-β signaling are enriched in super-enhancers,
which suggests that the lncRNAs controlled by TGF-β
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signaling may play key roles in HSC function and fibrosis.
TGF-β is a key activator of fibrosis [2] and this analysis
was performed on HSC myofibroblasts that underwent
transdifferentiation ex vivo as a model to identify human
lncRNAs regulated by TGF-β signaling. Now that these
lncRNAs have been defined, it will be important to iden-
tify and characterize those that are induced in human liver
disease.
Genes that control cell identity tend to be lineage-
restricted [109–114]. To identify additional lncRNAs
that may be key contributors to fibrosis progression, we
defined the lncRNAs enriched in HSC myofibroblasts.
We identified over 400 lncRNAs that are restricted in
expression to HSCs compared with 43 other tissues and
cell types. This analysis provides a more accurate repre-
sentation of cell-type specificity than the identification
of HSC lncRNAs that were not previously annotated
because ab initio assembly of lncRNA transcripts has
not been performed in all the tissues and cell types we
were able to analyze. By defining the lncRNAs that were
HSC-specific, bound by SMAD3, and associated with
super-enhancers, we were able to focus on a small set of
lncRNAs that are most likely to control HSC myofibro-
blast cell identity, which we refer to as identity lncRNAs.
Tracing these lncRNAs through the co-expression net-
work analysis allowed us to focus on the networks
containing lncRNAs most relevant to HSC function.
Co-expression network analysis revealed that lncRNAs
are co-expressed with protein-coding genes that regulate
production of ECM proteins. Over half the genes in this
network are lncRNAs and the network also includes
numerous collagen genes, whose products make up the
fibrotic scar, as well as proteins that are responsible for
crosslinking and remodeling the ECM. Co-expression
analysis was repeated in the absence of HSC expression
data and confirmed that the ECM network is present.
These findings indicate that the ECM network repre-
sents a robust co-expression network that is not identi-
fied solely based on high expression of genes in HSCs.
In addition, a subset of the lncRNAs in the ECM network
is induced in human liver fibrosis (Fig. 7c), suggesting that
they are associated with human liver disease. HSCs make
up only 5–10 % of the cells in the liver [115] and add-
itional lncRNAs are likely to be induced in HSCs during
the progression of fibrosis that were not detected in whole
liver samples due to lower levels of expression.
We found that lncRNA expression was highly conserved
between fetal and adult HSC myofibroblasts. In addition,
many lncRNAs were also shared between HSC myofibro-
blasts, pancreatic stellate cell myofibroblasts, and dermal
fibroblasts. Analysis of lncRNAs alone or lncRNAs and
protein-coding genes together revealed that fetal HSC
myofibroblasts were more closely related to adult HSC
myofibroblasts than to the other cell types analyzed. This
study focused on the identification of lncRNAs in HSC
myofibroblasts but also suggests that understanding the
role of lncRNAs in HSC myofibroblasts may lead to
insight into the function of lncRNAs in myofibroblasts
from other tissues.
Conclusions
We provide the first comprehensive catalog of lncRNAs
expressed in human HSCs and demonstrate that the
lncRNAs identified are relevant to human liver disease. We
discovered more than 3600 lncRNAs, including approxi-
mately 40 % that have not been described in other cell
types and greater than 400 that are uniquely enriched in
HSCs compared with 43 other tissues and cell types. We
analyzed the genomic location, chromatin modifications,
response to differentiation and signaling, and expression
across different tissues and cell types to identify lncRNAs
that are likely to be involved in HSC function and fibrosis.
This analysis provides a resource for future studies to in-
vestigate lncRNA function in liver disease and fibrosis.
Additional files
Additional file 1: Table S1. GTEx samples used in expression analyses.
(XLS 40 kb)
Additional file 2: Table S2. GTEx ID and pathology reads of eight
normal livers, two cirrhosis livers, and two bridging-fibrosis livers.
(XLS 22 kb)
Additional file 3: Supplemental Figures and legends. (PDF 3744 kb)
Additional file 4: Table S3. lncRNA transcripts and loci found in HSC
myofibroblasts. (XLS 1520 kb)
Additional file 5: Table S4. The genomic locations of super-enhancers.
(XLS 60 kb)
Additional file 6: Table S5. lncRNA transcripts and loci identified in
HSC myofibroblasts, HSC myofibroblasts during serum starvation, and
HSC myofibroblasts after TGF-β stimulation. (XLS 3456 kb)
Additional file 7: Table S6. Expression levels of all lncRNA loci in each
condition of HSC. (XLS 408 kb)
Additional file 8: Table S7. lncRNAs directly induced/repressed by
TGF-β signaling pathway. (XLSX 53 kb)
Additional file 9: Table S8. Expression profiles of HSC-specific lncRNAs
across HSC myofibroblasts, TGF-β HSCs, and 43 human tissues or cell
types. (XLS 389 kb)
Additional file 10: Table S9. lncRNAs’ association with SMAD3, super-
enhancers, and restricted expression in HSCs. (XLS 312 kb)
Additional file 11: Table S10. Co-expression pairs and gene lists of
major functional modules in clusters I, II and IV. (XLS 988 kb)
Additional file 12: Table S11. Expression levels of lncRNAs and their
divergent paired coding genes in HSC myofibroblasts. (XLS 310 kb)
Additional file 13: Table S12. Expression profile of divergently paired
protein-coding genes and lncRNAs that are co-expressed across 43
human tissues and cell types. (XLSX 533 kb)
Additional file 14: Table S13. The mean expression levels in FPKM of
lncRNAs in adult HSCs, PSCs, dermal fibroblasts, and livers. (XLSX 328 kb)
Additional file 15: Table S14. The expression levels in FPKM of lncRNAs
in TGF-β starvation and TGF-β treatment adult HSCs. (XLSX 250 kb)
Additional file 16: Table S15. H3K4me1:H3K4me3 ratio of the 851
lncRNAs in hiF cells. (XLS 78 kb)
Zhou et al. Genome Medicine  (2016) 8:31 Page 17 of 20
Abbreviations
ACTA2: actin, alpha2 smooth muscle; ChIP: chromatin immunoprecipitation;
DMEM: Dulbecco’s modified Eagle medium; ECM: extracellular matrix;
ENCODE: Encyclopedia of DNA Elements; eRNA: enhancer RNA; FCS: fetal
calf serum; FPKM: fragments per kilobase of transcript per million
fragments mapped; GEO: Gene Expression Omnibus; GO: Gene Ontology;
GTEx: Genotype-Tissue Expression; HCC: hepatocellular carcinoma;
hiF-T: human induced fibroblast; HSC: hepatic stellate cell; HUVEC: human
umbilical vein endothelial cell; kb: kilobase; lncRNA: long noncoding RNA;
logLR: log-likelihood ratio; LOX: lysyl oxidase; LOXL2: lysyl oxidase like 2;
MCL: Markov Clustering; mRNA: messenger RNA; ncRNA: noncoding RNA;
nt: nucleotide; P/S: penicillin/streptomycin; PC: principal component;
PCA: principal component analysis; snoRNA: small nucleolar RNA;
TGF-β: transforming growth factor beta; TSS: transcription start site;
UCSC: University of California, Santa Cruz.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
The project was conceived and directed by CZ and ACM. Data analysis was
performed by CZ with assistance from JVP and DLM. Cell culture work was
performed by SRY and JYC. Libraries were prepared for RNA sequencing by
SRY and JVP and microscopy was performed by JYC. The manuscript was
written by CZ and ACM with input from RTC. All authors read and approved
the final manuscript.
Acknowledgements
We thank Kaveh Daneshvar for helpful discussions and assistance with image
processing and Scott Friedman for helpful discussions and review of the
manuscript. We also thank Igor Ulitsky for advice on determining protein-
coding potential. We thank Massachusetts General Hospital (MGH) Next
Generation Sequencing Core for sequencing and the MGH Program in
Membrane Biology microscopy core. This project was supported by NIDDK
DK078772 and DK098079 (RTC) and the American Gastroenterological
Association Elsevier Pilot Award and Massachusetts General Hospital
Department of Medicine Transformative Scholar Award (ACM).
Received: 22 January 2016 Accepted: 3 March 2016
References
1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–18.
2. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic
cells of the liver. Physiol Rev. 2008;88:125–72.
3. Rojkind M, Martinez-Palomo A. Increase in type I and type III collagens in
human alcoholic liver cirrhosis. Proc Natl Acad Sci U S A. 1976;73:539–43.
4. Rojkind M, Giambrone M-A, Biempica L. Collagen types in normal and
cirrhotic liver. Gastroenterology. 1979;76:710–9.
5. Clement B, Grimaud J-A, Campion J-P, Deugnier Y, Guillouzo A. Cell types
involved in collagen and fibronectin production in normal and fibrotic
human liver. Hepatology. 1986;6:225–34.
6. Hahn E, Wick G, Pencev D, Timpl R. Distribution of basement membrane
proteins in normal and fibrotic human liver: collagen type IV, laminin, and
fibronectin. Gut. 1980;21:63–71.
7. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, et al.
Hepatic expression of mature transforming growth factor beta 1 in
transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A.
1995;92:2572–6.
8. Clouthier DE, Comerford SA, Hammer RE. Hepatic fibrosis, glomerulosclerosis,
and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. J Clin
Invest. 1997;100:2697–713.
9. Friedman SL, Roll FJ, Boylest J, Bissell DM. Hepatic lipocytes: the
principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci
U S A. 1985;82:8681–5.
10. Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al. Fate
tracing reveals hepatic stellate cells as dominant contributors to liver
fibrosis independent of its aetiology. Nat Commun. 2013;4:2823.
11. Friedman SL, Rockey DC, McGuire RF, Maher JJ, Boyles JK, Yamasaki G.
Isolated hepatic lipocytes and Kupffer cells from normal human liver:
morphological and functional characteristics in primary culture. Hepatology.
1992;15:234–43.
12. Uemura M, Swenson ES, Gaça MDA, Giordano FJ, Reiss M, Wells RG.
Smad2 and Smad3 play different roles in rat hepatic stellate cell
function and alpha-smooth muscle actin organization. Mol Biol Cell.
2005;16:4214–24.
13. Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, et al.
Myofibroblasts revert to an inactive phenotype during regression of
liver fibrosis. Proc Natl Acad Sci U S A. 2012;109:9448–53.
14. Troeger JS, Mederacke I, Gwak G-Y, Dapito DH, Mu X, Hsu CC, et al.
Deactivation of hepatic stellate cells during liver fibrosis resolution in mice.
Gastroenterology. 2012;143:1073–83. e22.
15. Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA. The
role of TGFβ1 in initiating hepatic stellate cell activation in vivo. J Hepatol.
1999;30:77–87.
16. Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P,
et al. TGF-beta 1 in liver fibrosis: an inducible transgenic mouse model
to study liver fibrogenesis. Am J Physiol Gastrointest Liver Physiol.
1999;276:G1059–1068.
17. Ueberham E, Löw R, Ueberham U, Schönig K, Bujard H, Gebhardt R.
Conditional tetracycline-regulated expression of TGF-beta1 in liver of
transgenic mice leads to reversible intermediary fibrosis. Hepatology.
2003;37:1067–78.
18. Schmitt-Gräff A, Krüger S, Bochard F, Gabbiani G, Denk H. Modulation of
alpha smooth muscle actin and desmin expression in perisinusoidal cells of
normal and diseased human livers. Am J Pathol. 1991;138:1233–42.
19. Rockey DC, Boyles JK, Gabbiani G, Friedman SL. Rat hepatic lipocytes
express smooth muscle actin upon activation in vivo and in culture.
J Submicrosc Cytol Pathol. 1992;24:193–203.
20. Perepelyuk M, Terajima M, Wang AY, Georges PC, Janmey PA, Yamauchi M,
et al. Hepatic stellate cells and portal fibroblasts are the major cellular
sources of collagens and lysyl oxidases in normal liver and early after injury.
Am J Physiol Gastrointest Liver Physiol. 2013;304:G605–14.
21. Liu X, Xu J, Brenner DA, Kisseleva T. Reversibility of liver fibrosis and
inactivation of fibrogenic myofibroblasts. Curr Pathobiol Rep. 2013;1:209–14.
22. Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al.
Landscape of transcription in human cells. Nature. 2012;489:101–8.
23. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev
Biochem. 2012;81:145–66.
24. Xie C, Yuan J, Li H, Li M, Zhao G, Bu D, et al. NONCODEv4: exploring the world of
long non-coding RNA genes. Nucleic Acids Res. 2014;42(Database issue):D98–103.
25. Brown CJ, Lafreniere RG, Powers VE, Sebastio G, Ballabio A, Pettigrew AL,
et al. Localization of the X inactivation centre on the human X chromosome in
Xq13. Nature. 1991;349:82–4.
26. Zhao J, Sun BK, Erwin JA, Song J-J, Lee JT. Polycomb proteins targeted by a
short repeat RNA to the mouse X chromosome. Science. 2008;322:750–6.
27. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, et al.
Many human large intergenic noncoding RNAs associate with chromatin-
modifying complexes and affect gene expression. Proc Natl Acad Sci U S A.
2009;106:11667–72.
28. Kretz M, Siprashvili Z, Chu C, Webster DE, Zehnder A, Qu K, et al. Control of
somatic tissue differentiation by the long non-coding RNA TINCR. Nature.
2013;493:231–5.
29. Yoon J-H, Abdelmohsen K, Kim J, Yang X, Martindale JL, Tominaga-
Yamanaka K, et al. Scaffold function of long non-coding RNA HOTAIR in
protein ubiquitination. Nat Commun. 2013;4:2939.
30. Wang P, Xue Y, Han Y, Lin L, Wu C, Xu S, et al. The STAT3-binding long
noncoding RNA lnc-DC controls human dendritic cell differentiation.
Science. 2014;344:310–3.
31. Li L, Liu B, Wapinski OL, Tsai M-C, Qu K, Zhang J, et al. Targeted disruption
of Hotair leads to homeotic transformation and gene derepression. Cell
Rep. 2013;5:3–12.
32. Sauvageau M, Goff LA, Lodato S, Bonev B, Groff AF, Gerhardinger C, et al.
Multiple knockout mouse models reveal lincRNAs are required for life and
brain development. Elife. 2013;2:1–24.
33. Klattenhoff CA, Scheuermann JC, Surface LE, Bradley RK, Fields PA,
Steinhauser ML, et al. Braveheart, a long noncoding RNA required for
cardiovascular lineage commitment. Cell. 2013;152:570–83.
34. Herriges MJ, Swarr DT, Morley MP, Rathi KS, Peng T, Stewart KM, et al. Long
noncoding RNAs are spatially correlated with transcription factors and
regulate lung development. Genes Dev. 2014;28:1363–79.
Zhou et al. Genome Medicine  (2016) 8:31 Page 18 of 20
35. Carpenter S, Aiello D, Atianand MK, Ricci EP, Gandhi P, Hall LL, et al. A long
noncoding RNA mediates both activation and repression of immune
response genes. Science. 2013;341:789–92.
36. Han P, Li W, Lin C-H, Yang J, Shang C, Nuernberg ST, et al. A long
noncoding RNA protects the heart from pathological hypertrophy.
Nature. 2014;514:102-6.
37. Du Z, Fei T, Verhaak RGW, Su Z, Zhang Y, Brown M, et al. Integrative
genomic analyses reveal clinically relevant long noncoding RNAs in human
cancer. Nat Struct Mol Biol. 2013;20:908–13.
38. Ponjavic J, Oliver PL, Lunter G, Ponting CP. Genomic and transcriptional
co-localization of protein-coding and long non-coding RNA pairs in the
developing brain. PLoS Genet. 2009;5:e1000617.
39. Panzitt K, Tschernatsch MMO, Guelly C, Moustafa T, Stradner M,
Strohmaier HM, et al. Characterization of HULC, a novel gene with
striking up-regulation in hepatocellular carcinoma, as noncoding RNA.
Gastroenterology. 2007;132:330–42.
40. Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a
marker for murine hepatocellular carcinomas and a spectrum of human
carcinomas. Oncogene. 2007;26:851–8.
41. Braconi C, Valeri N, Kogure T, Gasparini P, Huang N, Nuovo GJ, et al.
Expression and functional role of a transcribed noncoding RNA with an
ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci
U S A. 2011;108:786–91.
42. Yang F, Zhang L, Huo X, Yuan J, Xu D, Yuan S, et al. Long noncoding
RNA high expression in hepatocellular carcinoma facilitates tumor
growth through enhancer of zeste homolog 2 in humans. Hepatology.
2011;54:1679–89.
43. Yang Z, Zhou L, Wu L-M, Lai M-C, Xie H-Y, Zhang F, et al. Overexpression of
long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular
carcinoma patients following liver transplantation. Ann Surg Oncol.
2011;18:1243–50.
44. Yuan S-X, Yang F, Yang Y, Tao Q-F, Zhang J, Huang G, et al. Long
noncoding RNA associated with microvascular invasion in hepatocellular
carcinoma promotes angiogenesis and serves as a predictor for
hepatocellular carcinoma patients’ poor recurrence-free survival after
hepatectomy. Hepatology. 2012;56:2231–41.
45. Takahashi K, Yan IK, Haga H, Patel T. Modulation of hypoxia-signaling
pathways by extracellular linc-RoR. J Cell Sci. 2014;127:1585–94.
46. Quagliata L, Matter MS, Piscuoglio S, Arabi L, Ruiz C, Procino A, et al. Long
noncoding RNA HOTTIP/HOXA13 expression is associated with disease
progression and predicts outcome in hepatocellular carcinoma patients.
Hepatology. 2014;59:911–23.
47. Tsang FHC, Au SLK, Wei L, Fan DNY, Lee JMF, Wong CCL, et al. Long non-
coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma
and is targeted by tumour suppressive miR-125b. Liver Int. 2015;35:1597-606.
48. Mann DA. Epigenetics in liver disease. Hepatology. 2014;60:1418–25.
49. Lai M, Yang Z, Zhou L, Zhu Q, Xie H, Zhang F, et al. Long non-coding RNA
MALAT-1 overexpression predicts tumor recurrence of hepatocellular
carcinoma after liver transplantation. Med Oncol. 2012;29:1810–6.
50. Kogure T, Yan IK, Lin W-L, Patel T. Extracellular vesicle-mediated transfer of a
novel long noncoding RNA TUC339: a mechanism of intercellular signaling
in human hepatocellular cancer. Genes Cancer. 2013;4:261–72.
51. Xu D, Yang F, Yuan J, Zhang L, Bi H, Zhou C, et al. Long noncoding RNAs
associated with liver regeneration 1 accelerates hepatocyte proliferation
during liver regeneration by activating Wnt/β-catenin signaling. Hepatology.
2013;58:739–51.
52. He Y, Wu Y-T, Huang C, Meng X-M, Ma T-T, Wu B-M, et al. Inhibitory effects
of long noncoding RNA MEG3 on hepatic stellate cells activation and liver
fibrogenesis. Biochim Biophys Acta. 2014;1842(11):2204–15.
53. Yu F, Zheng J, Mao Y, Dong P, Lu Z, Li G, et al. Long non-coding RNA growth
arrest-specific transcript 5 (GAS5) inhibits liver fibrogenesis through a
mechanism of competing endogenous RNA. J Biol Chem. 2015;290:28286–98.
54. Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, et al.
microRNA-29 can regulate expression of the long non-coding RNA gene
MEG3 in hepatocellular cancer. Oncogene. 2011;30:4750–6.
55. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, et al.
Integrative annotation of human large intergenic noncoding RNAs reveals
global properties and specific subclasses. Genes Dev. 2011;25:1915–27.
56. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The
GENCODE v7 catalog of human long noncoding RNAs: analysis of their
gene structure, evolution, and expression. Genome Res. 2012;22:1775–89.
57. Hangauer MJ, Vaughn IW, McManus MT. Pervasive transcription of the
human genome produces thousands of previously unidentified long
intergenic noncoding RNAs. PLoS Genet. 2013;9:e1003569.
58. Sigova AA, Mullen AC, Molinie B, Gupta S, Orlando DA, Guenther MG.
Divergent transcription of long noncoding RNA/mRNA gene pairs in
embryonic stem cells. Proc Natl Acad Sci U S A. 2013;110:2876–81.
59. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with
RNA-Seq. Bioinformatics. 2009;25:1105–11.
60. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential
gene and transcript expression analysis of RNA-seq experiments with
TopHat and Cufflinks. Nat Protoc. 2012;7:562–78.
61. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al.
Transcript assembly and quantification by RNA-Seq reveals unannotated
transcripts and isoform switching during cell differentiation. Nat Biotechnol.
2010;28:511–5.
62. Guttman M, Garber M, Levin JZ, Donaghey J, Robinson J, Adiconis X, et al. Ab
initio reconstruction of cell type-specific transcriptomes in mouse reveals the
conserved multi-exonic structure of lincRNAs. Nat Biotechnol. 2010;28:503–10.
63. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The
Human Genome Browser at UCSC. Genome Res. 2002;12:996–1006.
64. Eddy SR. A new generation of homology search tools based on
probabilistic inference. Genome Inform. 2009;23:205–11.
65. Finn RD, Clements J, Eddy SR. HMMER web server: interactive sequence
similarity searching. Nucleic Acids Res. 2011;39(Web Server issue):W29–37.
66. Wang L, Park HJ, Dasari S, Wang S, Kocher J-P, Li W. CPAT: Coding-potential
assessment tool using an alignment-free logistic regression model. Nucleic
Acids Res. 2013;41:e74.
67. Finn RD, Bateman A, Clements J, Coggill P, Eberhardt RY, Eddy SR,
et al. Pfam: the protein families database. Nucleic Acids Res.
2014;42(Database issue):D222–30.
68. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2.
Nat Methods. 2012;9:357–9.
69. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al.
Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9:R137.
70. Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, et al.
Master transcription factors and mediator establish super-enhancers at key
cell identity genes. Cell. 2013;153:307–19.
71. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, et al. Super-
enhancers in the control of cell identity and disease. Cell. 2013;155:934–47.
72. Mercer TR, Gerhardt DJ, Dinger ME, Crawford J, Trapnell C, Jeddeloh JA,
et al. Targeted RNA sequencing reveals the deep complexity of the human
transcriptome. Nat Biotechnol. 2012;30:99–104.
73. Anders S, Pyl PT, Huber W. HTSeq–a Python framework to work with high-
throughput sequencing data. Bioinformatics. 2014;31:166–9.
74. Love MI, Huber W, Anders S. Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
75. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The
Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45:580–5.
76. van Dongen S, Abreu-Goodger C. Using MCL to extract clusters from
networks. Methods Mol Biol. 2012;804:281–95.
77. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, et al.
Integration of biological networks and gene expression data using
Cytoscape. Nat Protoc. 2007;2:2366–82.
78. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat
Protoc. 2009;4:44–57.
79. Jiao X, Sherman BT, Huang DW, Stephens R, Baseler MW, Lane HC, et al.
DAVID-WS: a stateful web service to facilitate gene/protein list analysis.
Bioinformatics. 2012;28:1805–6.
80. IIott NE, Heward JA, Roux B, Tsitsiou E, Fenwick PS, Lenzi L, et al. Long
non-coding RNAs and enhancer RNAs regulate the lipopolysaccharide-
induced inflammatory response in human monocytes. Nat Commun.
2014;5:3979.
81. Friedman SL, Roll FJ, Boyles J, Arenson DM, Bissell DM. Maintenance of
differentiated phenotype of cultured rat hepatic lipocytes by basement
membrane matrix. J Biol Chem. 1989;264:10756–62.
82. Sohara N, Znoyko I, Levy MT, Trojanowska M, Reuben A. Reversal of
activation of human myofibroblast-like cells by culture on a basement
membrane-like substrate. J Hepatol. 2002;37:214–21.
83. Ilott NE, Ponting CP. Predicting long non-coding RNAs using RNA
sequencing. Methods. 2013;63:50–9.
Zhou et al. Genome Medicine  (2016) 8:31 Page 19 of 20
84. Pruitt KD, Brown GR, Hiatt SM, Thibaud-Nissen F, Astashyn A, Ermolaeva O,
et al. RefSeq: an update on mammalian reference sequences. Nucleic Acids
Res. 2014;42(Database issue):D756–63.
85. Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, Haussler D,
et al. The UCSC Table Browser data retrieval tool. Nucleic Acids Res.
2004;32(Database issue):D493–6.
86. Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. A chromatin
landmark and transcription initiation at most promoters in human cells. Cell.
2007;130:77–88.
87. Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, Steine EJ,
et al. Histone H3K27ac separates active from poised enhancers and predicts
developmental state. Proc Natl Acad Sci U S A. 2010;107:21931–6.
88. Pauli A, Valen E, Lin MF, Garber M, Vastenhouw NL, Levin JZ, et al.
Systematic identification of long noncoding RNAs expressed during
zebrafish embryogenesis. Genome Res. 2012;22:577–91.
89. Massagué J, Seoane J, Wotton D. Smad transcription factors. Genes Dev.
2005;19:2783–810.
90. Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, et al.
A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response.
Cell. 2013;153:601–13.
91. Mullen AC, Orlando DA, Newman JJ, Lovén J, Kumar RM, Bilodeau S, et al.
Master transcription factors determine cell-type-specific responses to TGF-β
signaling. Cell. 2011;147:565–76.
92. Consortium TEP. A user’s guide to the encyclopedia of DNA elements
(ENCODE). PLoS Biol. 2011;9:e1001046.
93. Luo F, Yang Y, Zhong J, Gao H, Khan L, Thompson DK, et al. Constructing
gene co-expression networks and predicting functions of unknown genes
by random matrix theory. BMC Bioinformatics. 2007;8:299.
94. Sharan R, Ulitsky I, Shamir R. Network-based prediction of protein function.
Mol Syst Biol. 2007;3:88.
95. Wren JD. A global meta-analysis of microarray expression data to predict
unknown gene functions and estimate the literature-data divide.
Bioinformatics. 2009;25:1694–701.
96. Zhou C, Yin Y, Dam P, Xu Y. Identification of novel proteins involved in
plant cell-wall synthesis based on protein-protein interaction data.
J Proteome Res. 2010;9:5025–37.
97. Liao Q, Liu C, Yuan X, Kang S, Miao R, Xiao H, et al. Large-scale
prediction of long non-coding RNA functions in a coding-non-coding
gene co-expression network. Nucleic Acids Res. 2011;39:3864–78.
98. Ruan J, Dean AK, Zhang W. A general co-expression network-based
approach to gene expression analysis: comparison and applications. BMC
Systems Biol. 2010;4:8.
99. Guo X, Gao L, Liao Q, Xiao H, Ma X, Yang X, et al. Long non-coding RNAs
function annotation: a global prediction method based on bi-colored
networks. Nucleic Acids Res. 2013;41:e35.
100. Xiao X, Moreno-Moral A, Rotival M, Bottolo L, Petretto E. Multi-tissue analysis
of co-expression networks by higher-order generalized singular value
decomposition identifies functionally coherent transcriptional modules.
PLoS Genet. 2014;10:e1004006.
101. Lee HK, Hsu AK, Sajdak J, Qin J, Pavlidis P. Coexpression analysis
of human genes across many microarray data sets. Genome Res.
2004;14:1085–94.
102. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and
display of genome-wide expression patterns. Proc Natl Acad Sci U S A.
1998;95:14863–8.
103. Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, et al. Vitamin D
receptor-mediated stromal reprogramming suppresses pancreatitis and
enhances pancreatic cancer therapy. Cell. 2014;159:80–93.
104. Kim T-K, Hemberg M, Gray JM, Costa AM, Bear DM, Wu J, et al.
Widespread transcription at neuronal activity-regulated enhancers.
Nature. 2010;465:182–7.
105. Koch F, Fenouil R, Gut M, Cauchy P, Albert TK, Zacarias-Cabeza J, et al.
Transcription initiation platforms and GTF recruitment at tissue-specific
enhancers and promoters. Nat Struct Mol Biol. 2011;18:956–63.
106. Lam MTY, Li W, Rosenfeld MG, Glass CK. Enhancer RNAs and regulated
transcriptional programs. Trends Biochem Sci. 2014;39:170–82.
107. Cacchiarelli D, Trapnell C, Ziller MJ, Soumillon M, Cesana M, Karnik R, et al.
Integrative analyses of human reprogramming reveal dynamic nature of
induced pluripotency. Cell. 2015;162:412–24.
108. Cabili MN, Dunagin MC, McClanahan PD, Biaesch A, Padovan-Merhar O,
Regev A, et al. Localization and abundance analysis of human lncRNAs at
single-cell and single-molecule resolution. Genome Biol. 2015;16:20.
109. Lassar AB, Paterson BM, Weintraub H. Transfection of a DNA locus
that mediates the conversion of 10 T1/2 fibroblasts to myoblasts. Cell.
1986;47:649–56.
110. Kulessa H, Frampton J, Graf T. GATA-1 reprograms avian myelomonocytic
cell lines into eosinophils, thromboblasts, and erythroblasts. Genes Dev.
1995;9:1250–62.
111. Feng R, Desbordes SC, Xie H, Tillo ES, Pixley F, Stanley ER, et al. PU.1 and
C/EBPalpha/beta convert fibroblasts into macrophage-like cells. Proc Natl
Acad Sci U S A. 2008;105:6057–62.
112. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from
mouse embryonic and adult fibroblast cultures by defined factors. Cell.
2006;126:663–76.
113. Seale P, Bjork B, Yang W, Kajimura S, Chin S, Kuang S, et al. PRDM16 controls
a brown fat/skeletal muscle switch. Nature. 2008;454:961–7.
114. Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo reprogramming of
adult pancreatic exocrine cells to beta-cells. Nature. 2008;455:627–32.
115. Knook D, Seffelaar A, de Leeuw AM. Fat-storing cells of the rat liver. Their
isolation and purification. Exp Cell Res. 1982;139:468–71.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Zhou et al. Genome Medicine  (2016) 8:31 Page 20 of 20
